Multiple Sclerosis News

Biogen Idec Investigates Tysabri in Secondary-Progressive Multiple Sclerosis Patients

Biogen Idec is currently sponsoring a clinical trial evaluating its therapy Tysabri (natalizumab) in patients with secondary-progressive multiple sclerosis. Although relapse-remitting multiple sclerosis is more common and well-researched, the National Multiple Sclerosis Society estimates approximately half of relapse-remitting patients will transition to secondary-progressive within 19 years of diagnosis. The…

Novartis And Tictrac Raise Awareness For MS With Health Tracking Challenge

Pharmaceutical company Novartis and health tracking and analytics platform Tictrac recently partnered up to support World Multiple Sclerosis Day and raise awareness for this disease by launching the campaign The 7-Day Challenge to Live Like You. The challenge, one of the first integrations of emerging technological trends by a pharmaceutical…

Study Finds MS Drug Gilenya May Point To Development Of New PTSD Therapy

A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…

Committee for Medicinal Products for Human Use Adopts Positive Opinion For Plegridy As a Treatment for MS In The European Union

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recently offered a positive opinion for the marketing authorization of Biogen Idec’s Plegridy therapy, a pegylated interferon administered subcutaneously for adults with relapsing-remitting multiple sclerosis (RRMS). The positive opinion will now be sent to the European Commission, which grants…

Multiple Sclerosis Drug Nerventra® (Laquinimod) Disapproved in EU; Drug Developers Will Continue Research

Two pharmaceutical companies, Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech, have just confirmed reports that the Committee for Medicinal Products for Human Use (CHMP) is not recommending NERVENTRA (laquinimod) for use in treating relapsing-remitting multiple sclerosis (RRMS) within the European Union (EU), according to a recent press release. Despite CHMP’s disapproval of…

Newly Acquired Patents For Multiple Sclerosis, Alzheimer’s DNA Therapies Spurs New Clinical Trials At Inovio

Inovio Pharmaceuticals, a drug development company working on treatments that modulate therapeutically important immune responses with the help of T-cells, recently acquired the worldwide rights (apart from China), to conduct pre-clinical studies to produce products for possible therapies to treat and manage Alzheimer’s Disease (AD) and Multiple Sclerosis (MS).

MRI Spectroscopy May Improve Accuracy in Predicting MS Progression

A new study published this week in the Journal of the American Medical Association Neurology says that predicting disease evolution is becoming essential for optimizing treatment decision-making in multiple sclerosis (MS), in which pathologic damage typically includes demyelination, neuro-axonal loss, and astrogliosis. The study, entitled “Magnetic Resonance Spectroscopy…

New Secondary Progressive MS Drug Trial Completes Enrollment

Opexa Therapeutics, Inc., a drug delivery company based in The Woodlands, Texas, has been making significant progress in researching and developing Tcelna®, a breakthrough T-cell immunotherapy for multiple sclerosis (MS). The company recently announced they have reached their enrollment mark for conducting a Phase IIb clinical trial to test Tcelna as a viable…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here